Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2010

Open Access 01-12-2010 | Hypothesis

From 'omics' to complex disease: a systems biology approach to gene-environment interactions in cancer

Author: Sarah S Knox

Published in: Cancer Cell International | Issue 1/2010

Login to get access

Abstract

Background

Cancer is a complex disease that involves a sequence of gene-environment interactions in a progressive process that cannot occur without dysfunction in multiple systems, including DNA repair, apoptotic and immune functions. Epigenetic mechanisms, responding to numerous internal and external cues in a dynamic ongoing exchange, play a key role in mediating environmental influences on gene expression and tumor development.

Hypothesis

The hypothesis put forth in this paper addresses the limited success of treatment outcomes in clinical oncology. It states that improvement in treatment efficacy requires a new paradigm that focuses on reversing systemic dysfunction and tailoring treatments to specific stages in the process. It requires moving from a reductionist framework of seeking to destroy aberrant cells and pathways to a transdisciplinary systems biology approach aimed at reversing multiple levels of dysfunction.

Conclusion

Because there are many biological pathways and multiple epigenetic influences working simultaneously in the expression of cancer phenotypes, studying individual components in isolation does not allow an adequate understanding of phenotypic expression. A systems biology approach using new modeling techniques and nonlinear mathematics is needed to investigate gene-environment interactions and improve treatment efficacy. A broader array of study designs will also be required, including prospective molecular epidemiology, immune competent animal models and in vitro/in vivo translational research that more accurately reflects the complex process of tumor initiation and progression.
Literature
1.
Pedersen NL: The nature and nurture of personality. Personality Psychology in Europe. Edited by: De Raad B, Hofstee WKB, Van Heck GL. 1994, Tilburg: Tilburg University Press, 110-132.
2.
3.
4.
Riley T, Sontag E, Chen P, Levine A: Transcriptional control of human p53-regulated genes. Nature Reviews Molecular Cell Biology. 2008, 9 (5): 402-412. 10.1038/nrm2395.CrossRefPubMed
5.
Musani S, Shriner D, Liu N, Feng R, Coffey C, Yi N, Tiwari H, Allison D: Detection of gene× gene interactions in genome-wide association studies of human population data. Hum Hered. 2007, 63 (2): 67-84. 10.1159/000099179.CrossRefPubMed
6.
Gardner M, Bertranpetit J, Comas D: Worldwide genetic variation in dopamine and serotonin pathway genes: implications for association studies. American journal of medical genetics Part B, Neuropsychiatric genetics: the official publication of the International Society of Psychiatric Genetics. 2008, 147 (7): 1070.
7.
Testa B, Kier L, Carrupt P: A systems approach to molecular structure, intermolecular recognition, and emergence-dissolvence in medicinal research. Medicinal Research Reviews. 1997, 17 (4): 10.1002/(SICI)1098-1128(199707)17:4<303::AID-MED1>3.0.CO;2-#.
8.
Alberghina L, Höfer T, Vanoni M: Molecular networks and system-level properties. Journal of Biotechnology. 2009, 144 (3): 224-33. 10.1016/j.jbiotec.2009.07.009.CrossRefPubMed
9.
Poirier MG, Oh E, Tims HS, Widom J: Dynamics and function of compact nucleosome arrays. Nature Structural & Molecular Biology. 2009, 16 (9): 938-944. 10.1038/nsmb.1650.CrossRef
10.
Agutter P, Wheatley D: About Life: Concepts in Modern Biology. 2007, Dordrecht, The Netherlands: Springer
11.
Jirtle R, Skinner M: Environmental epigenomics and disease susceptibility. Nature reviews genetics. 2007, 8 (4): 253-262. 10.1038/nrg2045.CrossRefPubMed
12.
Voss A, Schroeder R, Truebner S, Goernig M, Figulla H, Schirdewan A: Comparison of nonlinear methods symbolic dynamics, detrended fluctuation, and Poincare plot analysis in risk stratification in patients with dilated cardiomyopathy. Chaos: An Interdisciplinary Journal of Nonlinear Science. 2007, 17: 015120-10.1063/1.2404633.CrossRef
13.
Peng C, Buldyrev S, Hausdorff J, Havlin S, Mietus J, Simons M, Stanley H, Goldberger A: Non-equilibrium dynamics as an indispensable characteristic of a healthy biological system. Integrative Psychological and Behavioral Science. 1994, 29 (3): 283-293. 10.1007/BF02691332.CrossRef
14.
Stanley H, Buldyrev S, Goldberger A, Havlin S, Peng C, Simons M: Scaling features of noncoding DNA. Physica A. 1999, 273 (1-2): 1-18. 10.1016/S0378-4371(99)00407-0.CrossRefPubMed
15.
Goldberger A, Amaral L, Hausdorff J, Ivanov P, Peng C, Stanley H: Fractal dynamics in physiology: alterations with disease and aging. National Acad Sciences. 2002, 99: 2466-2472. 10.1073/pnas.012579499.CrossRef
16.
Scheffer M, Bascompte J, Brock WA, Brovkin V, Carpenter SR, Dakos V, Held H, van Nes EH, Rietkerk M, Sugihara G: Early-warning signals for critical transitions. Nature. 2009, 461 (7260): 53. 10.1038/nature08227.
17.
Kirschner M: The meaning of systems biology. Cell. 2005, 121 (4): 503-504. 10.1016/j.cell.2005.05.005.CrossRefPubMed
18.
Ahn AC, Tewari M, Chi-Sang P, Phillips RS: The Limits of Reductionism in Medicine: Could Systems Biology Offer an Alternative?. PLoS Medicine. 2006, 3 (5): e208-0713. 10.1371/journal.pmed.0030208.PubMedCentralCrossRefPubMed
19.
Grigorov M: Global dynamics of biological systems from time-resolved omics experiments. 2006, Oxford Univ Press, 22: 1424-1430.
20.
Dollery CKR, Challis R, Delpy D, Edwards D, Henney A, Kirkwood T, Noble D, Rowland M, Tarassenko L, Williams D, Smith L: Systems biology: A vision for engineering and medicine. A Report from the Academy of Medical Sciences and the Royal Academy of Engineering. 2007
21.
Vera J, Wolkenhauer O: A systems biology approach to understand functional activity of cell communications systems. Methods in Cell Biology. 2008, 90: 399-415. full_text.CrossRefPubMed
22.
Kamb A, Wee S, Lengauer C: Why is cancer drug discovery so difficult?. Nature Reviews Drug Discovery. 2006, 6 (2): 115-120. 10.1038/nrd2155.CrossRefPubMed
23.
Schipper H, Goh C, Wang T: Shifting the cancer paradigm: must we kill to cure?. Journal of Clinical Oncology. 1995, 13 (4): 801-PubMed
24.
25.
Hoeijmakers J: DNA Damage, Aging, and Cancer. New England Journal of Medicine. 2009, 361 (15): 1475-10.1056/NEJMra0804615.CrossRefPubMed
26.
Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD: IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001, 410 (6832): 1107-10.1038/35074122.CrossRefPubMed
27.
Jeong H, Tombor B, Albert R, Oltvai Z, Barabasi A: The large-scale organization of metabolic networks. Nature. 2000, 407 (6804): 651-654. 10.1038/35036627.CrossRefPubMed
28.
Chauvet G: Hierarchical functional organization of formal biological systems: A dynamical approach. I. The increase of complexity by self-association increases the domain of stability of a biological system. Philosophical Transactions: Biological Sciences. 1993, 339 (1290): 425-444. 10.1098/rstb.1993.0040.CrossRef
29.
Callinan PA, Feinberg AP: The emerging science of epigenomics. Human Molecular Genetics. 2006, 15 (Spec No 1): R95-101. 10.1093/hmg/ddl095.CrossRefPubMed
30.
Baylin SB, Chen WY: Aberrant Gene Silencing in Tumor Progression: Implications for Control of Cancer. Cold Spring Harbor Symposia on Quantitative Biology. 2005, 70: 427-433. 10.1101/sqb.2005.70.010.CrossRefPubMed
31.
Jones P, Baylin S: The fundamental role of epigenetic events in cancer. Nature reviews genetics. 2002, 3 (6): 415-428.PubMed
32.
33.
Feinberg A, Ohlsson R, Henikoff S: The epigenetic progenitor origin of human cancer. Nature reviews genetics. 2006, 7 (1): 21-33. 10.1038/nrg1748.CrossRefPubMed
34.
Bjornsson HT, Daniele Fallin M, Feinberg AP: An integrated epigenetic and genetic approach to common human disease. Trends in Genetics. 2004, 20 (8): 350-358. 10.1016/j.tig.2004.06.009.CrossRefPubMed
35.
Burns D: Tobacco-related diseases. 2003, Elsevier, 244-249.
36.
Gan Q, Smith K, Hammond S, Hu T: Disease burden of adult lung cancer and ischaemic heart disease from passive tobacco smoking in China. British Medical Journal. 2007, 16 (6): 417-
37.
Alberg AJ, Samet JM: Epidemiology of Lung Cancer. CHEST. 2003, 123: 21S-10.1378/chest.123.1_suppl.21S.CrossRefPubMed
38.
Mattson M, Pollack E, Cullen J: What are the odds that smoking will kill you?. Am Public Health Assoc. 1987, 77: 425-431. 10.2105/AJPH.77.4.425.CrossRef
39.
Subramanian J, Govindan R: Lung cancer in never smokers: a review. Journal of Clinical Oncology. 2007, 25 (5): 561-10.1200/JCO.2006.06.8015.CrossRefPubMed
40.
Parkin D, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA: a cancer journal for clinicians. 2005, 55 (2): 74-108. 10.3322/canjclin.55.2.74.
41.
Sellers T, Elston R, Stewart C, Rothschild H, Vogler G: Familial risk of cancer among randomly selected cancer probands. Genetic epidemiology. 1988, 5 (6): 10.1002/gepi.1370050603.
42.
Tokuhata G, Lilienfeld A: Familial aggregation of lung cancer in humans. Journal of the National Cancer Institute. 1963, 30: 289-PubMed
43.
Guo H: Arsenic level in drinking water and mortality of lung cancer (Taiwan). Cancer Causes and Control. 2004, 15 (2): 171-177. 10.1023/B:CACO.0000019503.02851.b0.CrossRefPubMed
44.
Hertz-Picciotto I, Smith A: Observations on the dose-response curve for arsenic exposure and lung cancer. Scandinavian journal of work, environment & health. 1993, 19 (4): 217-226.CrossRef
45.
Ekberg-Aronsson M, Nilsson P, Nilsson J, Pehrsson K, Löfdahl C: Socio-economic status and lung cancer risk including histologic subtyping--a longitudinal study. Lung cancer. 2006, 51 (1): 21-29. 10.1016/j.lungcan.2005.08.014.CrossRefPubMed
46.
Ross S: Diet and DNA methylation interactions in cancer prevention. Annals of the New York Academy of Sciences. 2003, 983: 197-207. 10.1111/j.1749-6632.2003.tb05974.x.CrossRefPubMed
47.
Choi S, Mason J: Folate status: effects on pathways of colorectal carcinogenesis. The Journal of nutrition. 2002, 132 (8 Suppl): 2413S-PubMed
48.
Harnack L, Jacobs D, Nicodemus K, Lazovich D, Anderson K, Folsom A: Relationship of folate, vitamin B-6, vitamin B-12, and methionine intake to incidence of colorectal cancers. Nutrition and cancer. 2002, 43 (2): 152-10.1207/S15327914NC432_5.CrossRefPubMed
49.
Brunaud L, Alberto JM, Ayav A, Gerard P, Namour F, Antunes L, Braun M, Bronowicki JP, Bresler L, Gueant JL: Effects of vitamin B12 and folate deficiencies on DNA methylation and carcinogenesis in rat liver. Clinical Chemistry & Laboratory Medicine. 2003, 41 (8): 1012-1019. 10.1515/CCLM.2003.155.CrossRef
50.
Lyn-Cook B, Blann E, Payne P, Bo J, Sheehan D, Medlock K: Methylation profile and amplification of proto-oncogenes in rat pancreas induced with phytoestrogens. SEBM. 1995, 208: 116-119.
51.
Fang MZ, Wang YM, Ai N, Hou Z, Sun Y, Lu H, Welsh W, Yang CS: Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Research. 2003, 63 (22): 7563-7570.PubMed
52.
Fang MZ, Chen D, Sun Y, Christman JK, Yang CS: Reversal of hypermethylation and reactivation of p16-INK4a, RAR, and MGMT genes by genistein and other isoflavones from soy. Clin Cancer Res. 2005, 11: 7033-7041. 10.1158/1078-0432.CCR-05-0406.CrossRefPubMed
53.
Yang CS, Fang M, Lambert JD, Yan P, Huang THM: Reversal of hypermethylation and reactivation of genes by dietary polyphenolic compounds. Nutrition Reviews. 2008, 66: S18-10.1111/j.1753-4887.2008.00059.x.PubMedCentralCrossRefPubMed
54.
Belinsky SA: Gene-promoter hypermethylation as a biomarker in lung cancer. Nature Reviews Cancer. 2004, 4 (9): 707-717. 10.1038/nrc1432.CrossRefPubMed
55.
Rea S, Eisenhaber F, O'Carroll D, Strahl B, Sun Z, Schmid M, Opravil S, Mechtler K, Ponting C, Allis C: Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature. 2000, 406 (6796): 593-599. 10.1038/35020506.CrossRefPubMed
56.
Candido E, Reeves R, Davie J: Sodium butyrate inhibits histone deacetylation in cultured cells. Cell. 1978, 14 (1): 105-113. 10.1016/0092-8674(78)90305-7.CrossRefPubMed
57.
Demary K, Wong L, Spanjaard RA: Effects of retinoic acid and sodium butyrate on gene expression, histone acetylation and inhibition of proliferation of melanoma cells. Cancer Letters. 2001, 163 (1): 103-107. 10.1016/S0304-3835(00)00676-5.CrossRefPubMed
58.
Li M: Identifying susceptibility loci for nicotine dependence: 2008 update based on recent genome-wide linkage analyses. Human Genetics. 2008, 123 (2): 119-131. 10.1007/s00439-008-0473-0.CrossRefPubMed
59.
Wang-Sattler R, Yu Y, Mittelstrass K, Lattka E, Altmaier E, Gieger C, Ladwig K, Dahmen N, Weinberger K, Hao P: Metabolic Profiling Reveals Distinct Variations Linked to Nicotine Consumption in Humans--First Results from the KORA Study. PLoS One. 2008, 3 (12): 10.1371/journal.pone.0003863.
60.
Schembri F, Sridhar S, Perdomo C, Gustafson A, Zhang X, Ergun A, Lu J, Liu G, Bowers J: MicroRNAs as modulators of smoking-induced gene expression changes in human airway epithelium. Proceedings of the National Academy of Sciences. 2009, 106 (7): 2319-10.1073/pnas.0806383106.CrossRef
61.
Daskalos A, Nikolaidis G, Xinarianos G, Savvari P, Cassidy A, Zakopoulou R, Kotsinas A, Gorgoulis V, Field JK, Liloglou T: Hypomethylation of retrotransposable elements correlates with genomic instability in non-small cell lung cancer. International Journal Of Cancer Journal International Du Cancer. 2009, 124 (1): 81-87. 10.1002/ijc.23849.CrossRefPubMed
62.
Sidley C, Picchi M, Leng S, Willink R, Crowell R, Flores K, Kang H, Byers T, Gilliland F, Belinsky S: Multi-vitamins, folate, and Green vegetables protect against gene promoter methylation in the aerodigestive tract of smokers. Cancer Research. 2010, 70 (2): 568-574. 10.1158/0008-5472.CAN-09-3410.CrossRef
63.
Divine KK, Pulling LC, Marron-Terada PG, Liechty KC, Kang T, Schwartz AG, Bocklage TJ, Coons TA, Gilliland FD, Belinsky SA: Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers. International Journal Of Cancer Journal International Du Cancer. 2005, 114 (3): 400-405. 10.1002/ijc.20761.CrossRefPubMed
64.
Zöchbauer-Müller S, Fong K, Virmani A, Geradts J, Gazdar A, Minna J: Aberrant promoter methylation of multiple genes in non-small cell lung cancers. AACR. 2001, 61: 249-255.
65.
Feinberg A: Phenotypic plasticity and the epigenetics of human disease. Nature. 2007, 447 (7143): 433-440. 10.1038/nature05919.CrossRefPubMed
66.
Suzuki H, Ueda R, Takahashi T: Altered imprinting in lung cancer. Nature Genetics. 1994, 6 (4): 332-333. 10.1038/ng0494-332.CrossRefPubMed
67.
Kohda M, Hoshiya H, Katoh M, Tanaka I, Masuda R, Takemura T, Fujiwara M, Oshimura M: Frequent loss of imprinting of IGF2 and MEST in lung adenocarcinoma. Molecular Carcinogenesis. 2001, 31 (4): 10.1002/mc.1053.
68.
Herman J, Baylin S: Gene silencing in cancer in association with promoter hypermethylation. New England Journal of Medicine. 2003, 349 (21): 2042-2054. 10.1056/NEJMra023075.CrossRefPubMed
69.
Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB: Tumor Suppressor HIC1 Directly Regulates SIRT1 to Modulate p53-Dependent DNA-Damage Responses. Cell. 2005, 123 (3): 437-448. 10.1016/j.cell.2005.08.011.CrossRefPubMed
70.
Chen WY, Baylin SB: Inactivation of tumor suppressor genes: choice between genetic and epigenetic routes. Cell Cycle (Georgetown, Tex). 2005, 4 (1): 10-12.CrossRef
71.
Bartek J, Lukas J: The Stress of Finding NEMO. Science. 2006, 311 (5764): 1110-1111. 10.1126/science.1124540.CrossRefPubMed
72.
Garzon R, Calin GA, Croce CM: MicroRNAs in Cancer. Annual Review Of Medicine. 2009, 60: 167-179. 10.1146/annurev.med.59.053006.104707.CrossRefPubMed
73.
Drakaki A, Iliopoulos D: MicroRNA Gene Networks in Oncogenesis. 2009, 10 (1): 35-41.
74.
Vasilatou D, Papageorgiou S, Pappa V, Papageorgiou E, Dervenoulas J: The role of microRNAs in normal and malignant hematopoiesis. European Journal of Haematology. 2009, 9999 (9999):
75.
Mott J: MicroRNAs involved in tumor suppressor and oncogene pathways; implications for hepatobiliary neoplasia. Hepatology. 2009, 50 (2): 630-7. 10.1002/hep.23010.PubMedCentralCrossRefPubMed
76.
Cotter T: Apoptosis and cancer: the genesis of a research field. Nature Reviews Cancer. 2009, 9 (7): 501-507. 10.1038/nrc2663.CrossRefPubMed
77.
Danial NN: BAD: undertaker by night, candyman by day. Oncogene. 2008, 27 (Suppl 1): S53-70. 10.1038/onc.2009.44.CrossRefPubMed
78.
Tse C, Shoemaker A, Adickes J, Anderson M, Chen J, Jin S, Johnson E, Marsh K, Mitten M, Nimmer P: ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Research. 2008, 68 (9): 3421-10.1158/0008-5472.CAN-07-5836.CrossRefPubMed
79.
Shoemaker A, Mitten M, Adickes J, Ackler S, Refici M, Ferguson D, Oleksijew A, O'Connor J, Wang B, Frost D: Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clinical Cancer Research. 2008, 14 (11): 3268-10.1158/1078-0432.CCR-07-4622.CrossRefPubMed
80.
Garofalo M, Condorelli G, Croce C, Condorelli G: MicroRNAs as regulators of death receptors signaling. Cell Death & Differentiation. 2009, 17 (2): 200-8. 10.1038/cdd.2009.105.CrossRef
81.
Galluzzi LME, Kepp O, Vitalio Rigoni A, Vacchelli E: Mitchondrial gateways to cancer. MOlecular Aspects of Medicine. 2009, 31 (1): 1-20. 10.1016/j.mam.2009.08.002.CrossRefPubMed
82.
Chen SS, RavaI A, Johnson AJ, Hertlein E, Te-Hui L, Jin VX, Sherman MH, Shu-Jun L, Dawson DW, Williams KE: Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America. 2009, 106 (32): 13433-13438. 10.1073/pnas.0906455106.PubMedCentralCrossRefPubMed
83.
McEwen B: Interacting mediators of allostasis and allostatic load: towards an understanding of resilience in aging. Metabolism. 2003, 52: 10-16. 10.1053/S0026-0495(03)00295-6.CrossRefPubMed
84.
McEwen B, Stellar E: Stress and the individual: mechanisms leading to disease. Archives of Internal Medicine. 1993, 153 (18): 2093-10.1001/archinte.153.18.2093.CrossRefPubMed
85.
McEwen B: Protective and damaging effects of stress mediators. New England Journal of Medicine. 1998, 338 (3): 171-179. 10.1056/NEJM199801153380307.CrossRefPubMed
86.
Bjartveit K, Tverdal A: Health consequences of sustained smoking cessation. British Medical Journal. 2009, 18 (3): 197-
87.
Szanton S, Gill J, Allen J: Allostatic Load: A Mechanism of Socioeconomic Health Disparities?. Biological Research for Nursing. 2005, 7 (1): 7-10.1177/1099800405278216.PubMedCentralCrossRefPubMed
88.
Geyer S: Social inequalities in the incidence and case fatality of cancers of the lung, the stomach, the bowels, and the breast. Cancer Causes and Control. 2008, 19 (9): 965-974.CrossRefPubMed
89.
Chu KC, Miller BA, Springfield SA: Measures of racial/ethnic health disparities in cancer mortality rates and the influence of socioeconomic status. Journal of the National Medical Association. 2007, 99 (10): 1092-1104.PubMedCentralPubMed
90.
Lewis DR, Clegg LX, Johnson NJ: Lung disease mortality in the United States: the National Longitudinal Mortality Study. The International Journal Of Tuberculosis And Lung Disease: The Official Journal Of The International Union Against Tuberculosis And Lung Disease. 2009, 13 (8): 1008-1014.
91.
Hausauer AK, Keegan T, Chang ET, Glaser SL, Howe H, Clarke CA: Recent trends in breast cancer incidence in US white women bycounty-level urban/rural and poverty status. BMC Medicine. 2009, 7: 31-42. 10.1186/1741-7015-7-31.PubMedCentralCrossRefPubMed
92.
Warnakulasuriya S: Significant oral cancer risk associated with low socioeconomic status. Evidence-Based Dentistry. 2009, 10 (1): 4-5. 10.1038/sj.ebd.6400623.CrossRefPubMed
93.
Frederiksen B, Osler M, Harling H, Ladelund S, Jørgensen T: The impact of socioeconomic factors on 30-day mortality following elective colorectal cancer surgery: A nationwide study. European Journal of Cancer. 2009, 45 (7): 1248-1256. 10.1016/j.ejca.2008.11.035.CrossRefPubMed
94.
Siegel RL, Jemal A, Thun MJ, Hao Y, Ward EM: Trends in the incidence of colorectal cancer in relation to county-level poverty among blacks and whites. Journal of the National Medical Association. 2008, 100 (12): 1441-1444.PubMed
95.
Ou S-HI, Ziogas A, Zell JA: Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity. Journal Of Thoracic Oncology: Official Publication Of The International Association For The Study Of Lung Cancer. 2009, 4 (1): 37-43.CrossRef
96.
Cherkas LF, Aviv A, Valdes AM, Hunkin JL, Gardner JP, Surdulescu GL, Kimura M, Spector TD: The effects of social status on biological aging as measured by white-blood-cell telomere length. Aging Cell. 2006, 5 (5): 361-365. 10.1111/j.1474-9726.2006.00222.x.CrossRefPubMed
97.
Epel ES, Lin J, Wilhelm FH, Wolkowitz OM, Cawthon R, Adler NE, Dolbier C, Mendes WB, Blackburn EH: Cell aging in relation to stress arousal and cardiovascular disease risk factors. Psychoneuroendocrinology. 2006, 31 (3): 277-287. 10.1016/j.psyneuen.2005.08.011.CrossRefPubMed
98.
Chen E, Hanson MD, Paterson LQ, Griffin MJ, Walker HA, Miller GE: Socioeconomic status and inflammatory processes in childhood asthma: the role of psychological stress. The Journal Of Allergy And Clinical Immunology. 2006, 117 (5): 1014-1020. 10.1016/j.jaci.2006.01.036.CrossRefPubMed
99.
Pretscher D, Distel L, Grabenbauer G, Wittlinger M, Buettner M, Niedobitek G: Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro-and hypopharyngeal carcinoma. BMC cancer. 2009, 9 (1): 292-10.1186/1471-2407-9-292.PubMedCentralCrossRefPubMed
100.
Dhabhar F, Mcewen B: Acute Stress Enhances while Chronic Stress Suppresses Cell-Mediated Immunityin Vivo: A Potential Role for Leukocyte Trafficking. Brain Behavior and immunity. 1997, 11 (4): 286-306. 10.1006/brbi.1997.0508.CrossRef
Metadata
Title
From 'omics' to complex disease: a systems biology approach to gene-environment interactions in cancer
Author
Sarah S Knox
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2010
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-10-11

Other articles of this Issue 1/2010

Cancer Cell International 1/2010 Go to the issue

Primary research

Bradykinin increases resensitization of purinergic receptor signaling in glioma cells

Primary research

Transformation of SV40-immortalized human uroepithelial cells by 3-methylcholanthrene increases IFN- and Large T Antigen-induced transcripts

Primary research

A natural compound from Hydnophytum formicarium induces apoptosis of MCF-7 cells via up-regulation of Bax

Primary research

Targeting the angiotensin II type 2 receptor (AT2R) in colorectal liver metastases

Primary research

ASPM-associated stem cell proliferation is involved in malignant progression of gliomas and constitutes an attractive therapeutic target

Primary research

Kaempferol enhances cisplatin's effect on ovarian cancer cells through promoting apoptosis caused by down regulation of cMyc
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits